# Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

> **NCT03914612** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 813 (actual)

## Conditions studied

- Endometrial Clear Cell Adenocarcinoma
- Endometrial Dedifferentiated Carcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Undifferentiated Carcinoma
- Recurrent Endometrial Adenocarcinoma
- Recurrent Endometrial Carcinoma
- Recurrent Endometrial Clear Cell Adenocarcinoma
- Recurrent Endometrial Dedifferentiated Carcinoma
- Recurrent Endometrial Endometrioid Adenocarcinoma
- Recurrent Endometrial Mixed Cell Adenocarcinoma
- Recurrent Endometrial Serous Adenocarcinoma
- Recurrent Endometrial Undifferentiated Carcinoma
- Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

## Interventions

- **DRUG:** Carboplatin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03914612
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-22
- **Primary completion:** 2022-12-16
- **Final completion:** 2026-09-26
- **Target enrollment:** 813 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03914612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03914612, "Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03914612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*